Fluorescein Angiographic Findings of Peripheral Retinal Vasculature after Intravitreal Conbercept versus Ranibizumab for Retinopathy of Prematurity

Figure 2

Fluorescein angiographic images of infants receive IVR therapy. (a) Fluorescein angiographic images of an infant (no. 1 in IVR group) born at 28.29 weeks’ gestational age who had zone ii stage 3 ROP with plus disease. Primary intravitreal injection of ranibizumab was performed at 38.86 weeks. Fluorescein angiography at 66.29 weeks PMA exhibits persistent avascular zone (closed arrowhead), vascular leakage (double arrow), vascular blunting (arrow), vascular loops (asterisk), and capillary dropout (open arrowhead). (b) Fluorescein angiographic images of an infant (No. 7 in IVR group) born at 27.86 weeks’ gestational age who had Zone II Stage 3 ROP with plus disease. Primary intravitreal injection of ranibizumab was performed at 39.00 weeks. Fluorescein angiography at 70.86 weeks PMA exhibits persistent avascular zone (closed arrowhead), vascular leakage (double arrow) and vascular dilation (arrow).

(a)

(b)